KYNAM CAPITAL MANAGEMENT LP
Q3 2024 Form 13-F

PRINCETON, NEW JERSEY
CIK 0001907884 · CRD 314368 · SEC-registered investment adviser
$1.3B Reported Value Total

KYNAM CAPITAL MANAGEMENT, LP reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $1,833,940,841, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-04-10
Reported value
$1.3B
Quarter over quarter
+15.4%
Holdings
24
Top-10 concentration
81.5%

Key People

Form ADV owners & control persons
Yue "nmn" Tang
LIMITED PARTNER
Jared Joseph Keller
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2024 13F record

Q3 2024 13F filing summary

Q3 2024 Form 13F portfolio summary
Period of report September 30, 2024
Filed November 14, 2024
Form 13F-HR
Reported value $1.3B
Positions 24
Change in reported value +0.6%
New positions 2
Exited positions 0
Position turnover 8.3%
Top-10 concentration 81.5%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
34 $1.8B
Q2 2026 13F
Filed Aug 14, 2026
32 $1.8B
Q1 2026 13F
Filed May 15, 2026
36 $1.6B
Q4 2025 13F
Filed Feb 17, 2026
35 $1.6B
Q3 2025 13F
Filed Nov 14, 2025
35 $1.3B
Q2 2025 13F
Filed Aug 14, 2025
31 $928.8M
Q1 2025 13F
Filed May 15, 2025
31 $1.2B
Q4 2024 13F
Filed Feb 14, 2025
29 $1.7B
Q3 2024 13F
Filed Nov 14, 2024
24 $1.3B
Q2 2024 13F
Filed Aug 14, 2024
22 $1.3B
Q1 2024 13F
Filed May 15, 2024
21 $955.5M
Q4 2023 13F
Filed Feb 14, 2024
23 $902.6M
Q3 2023 13F
Filed Nov 14, 2023
27 $611.4M
Q2 2023 13F
Filed Aug 14, 2023
23 $727.1M
Q1 2023 13F
Filed May 15, 2023
34 $774.6M
Q4 2022 13F
Filed Feb 14, 2023
31 $651.9M
Q3 2022 13F
Filed Nov 14, 2022
33 $474.6M
Q2 2022 13F
Filed Aug 15, 2022
31 $391.6M
Q1 2022 13F
Filed May 13, 2022
31 $308.3M
Q4 2021 13F
Filed Feb 14, 2022
30 $187.1M

Top 20 holdings · Q3 2024

Largest Q3 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 NTRA NATERA INC $259.3M 19.88%
2 PCVX VAXCYTE INC $118.8M 9.1%
3 CLDX CELLDEX THERAPEUTICS INC NEW $117.6M 9.01%
4 SNDX SYNDAX PHARMACEUTICALS INC $112.5M 8.62%
5 COGT COGENT BIOSCIENCES INC $99.8M 7.65%
6 DVAX DYNAVAX TECHNOLOGIES CORP $92.8M 7.12%
7 VERA VERA THERAPEUTICS INC $69.7M 5.34%
8 BCRX BIOCRYST PHARMACEUTICALS INC $69.0M 5.29%
9 CGON CG ONCOLOGY INC $66.8M 5.12%
10 VRDN VIRIDIAN THERAPEUTICS INC $57.1M 4.38%
11 WVE WAVE LIFE SCIENCES LTD $40.2M 3.08%
12 BEAM BEAM THERAPEUTICS INC $31.9M 2.45%
13 TSVT 2SEVENTY BIO INC $28.1M 2.15%
14 LQDA LIQUIDIA CORPORATION $22.7M 1.74%
15 PTGX PROTAGONIST THERAPEUTICS INC $20.5M 1.57%
16 TVTX TRAVERE THERAPEUTICS INC $19.2M 1.47%
17 IRWD IRONWOOD PHARMACEUTICALS INC $15.2M 1.16%
18 VRTX P VERTEX PHARMACEUTICALS INC $14.0M 1.07%
19 ENGN ENGENE HOLDINGS INC $11.5M 0.88%
20 TYRA TYRA BIOSCIENCES INC $11.0M 0.84%

Values as reported on the Q3 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings